Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
· nasus pharma, ltd.
AI Briefing
- NS002 demonstrates significantly faster epinephrine delivery (1.69 minutes vs 3.42 minutes) and higher percentage of subjects reaching therapeutic threshold (88.4% vs 64.6%) compared to EpiPen.
Advertisement